Skip to contentM
Medifast Inc
M
MEDMedifast Inc Q4 2025 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$75.10M$75.10Mderived−36.9% vs Q4 2024 Net Income-$18.12M-$18.12MderivedN/M vs Q4 2024 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Medifast Inc · CIK 910329 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Gross Profitderived$52,139,000−40.9% Operating Incomederived-$7,804,000N/M Operating Cash Flowderived-$5,278,000N/M Free Cash Flowderived-$6,629,000N/M Margins · derivedGross margin69.4%−4.7 pt vs Q4 2024
Operating margin-10.4%−11.0 pt vs Q4 2024
Net margin-24.1%−24.8 pt vs Q4 2024
ended Dec 31, 2025 · filed Feb 17, 2026 · 48 d after period end